Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1479-1487

  Müller, Volkmar ^a,e   Witzel, Isabell ^a   Pantel, Klaus ^a   Krenkel, Sylke ^a   Lück, Hans Joachim ^b   Neumann, Rainer ^c   Keller, Thomas ^d   Dittmer, Jürgen ^e   Jänicke, Fritz ^a   Thomssen, Christoph ^a,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BAYER AG   (Germany)

^d AddStat   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Breast cancer; Epidermal growth factor receptor; Serum

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SOLUBILITY;

EID: 33645817562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2001.
2. de Bono JS and Rowinsky EK: The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 8: S19-26, 2002.
3. Arteaga CL: EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21: 289s-291s, 2003.
4. Lin NU and Winer EP: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 6: 204-210, 2004.
5. Pawlowski V, Revillion F, Hebbar M, Hornez L and Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6: 4217-4225, 2000.
6. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D and Harris AL: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29: 41-49, 1994.
7. Klijn JG, Berns PM, Schmitz PI and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 3-17, 1992.
8. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR and Cooke TG: Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6: R246-251, 2004.
9. Newby JC, Johnston SR, Smith IE and Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997.
10. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO and Blarney RW: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125, 1994.
11. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB and Rose C: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19: 3376-3384, 2001.
12. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE and Nicholson RI: Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81: 81-93, 2003.
13. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P and Carney W: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21: 1967-1972, 2003.
14. Müller V, Witzel I, Lück H, Köhler G, vMinckwitz G, Möbus V, Sattler D, Löning T, Wilczak W, Jänicke F, Pantel K and Thomssen C: Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 86: 9-18, 2004.
15. Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Mobus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Janicke F and Slamon DJ: Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96: 1141-1151, 2004.
16. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC and Maihle NJ: Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12: 103-113, 2003.
17. Carney W, Burrell M, Morris LD and Hamer P: Normal levels of serum EGFR and decreases in several cancers. Proc AACR 43: 240, 2002.
18. Oh MJ, Choi JH, Kim IH, Lee YH, Huh JY, Park YK, Lee KW, Chough SY, Joo KS, Ku BS and Saw HS: Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 6: 4760-4763, 2000.
19. Sasaki H, Yukiue H, Sekimura A, Mizuno K, Konishi A, Yano M. Fukai I and Fujii Y: Elevated serum epidermal growth factor receptor level in stage IV thymoma. Surg Today 34: 477-479, 2004.
20. Jacot W, Pujol JL, Boher JM and Lamy PJ: Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. Br J Cancer 91: 430-433, 2004.
21. Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN and Maihle NJ: Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 65: 3059-3062, 2005.
22. Gregore V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crino L, Tonato M and Villa E: Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 10: 6006-6012, 2004.
23. Esteva FJ, Cheli CD, Pritsche H, Fornier M, Slamon D, Thiel R, Lüftner D and Ghani F: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Can Res 7: R436-R443, 2005.
24. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W and Al lard J: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-1472, 2002.
25. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S and Price CP: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49: 1579-1598, 2003.
26. Fehm T, Jager W, Kramer S, Sohn C, Solomayer E, Wallwiener D and Gebauer G: Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 24: 1987-1992, 2004.
27. Fehm T, Jäger W, Kraemer S, Sohn C, Solomayer-Meyberg G, Solomayer EF, Kurek R, Wallwiener D and Gebauer G: Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res 24: 4205-4210, 2004.
28. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
29. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E and Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808-3816, 2001.
30. Stearns V, Yamauchi H and Hayes DF: Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 52: 239-259, 1998.
31. Luck HJ, Thomssen C, Untch M, Kuhn W, Eidtmann H, DuBois A, Olbricht S, Möbus V, Steinfeld D, Bauknecht T, Schroeder W and Jackisch C: Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC), epirubicm/paclitaxel (ET) vs. epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proceeings of ASCO, Abstract No. 280, 2000.
32. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Ferez EA and Maihle NJ: A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev 10: 1175-1185, 2001.
33. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D and Hutcheson I: The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80 Suppl 1: S29-34, 2003.
34. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE and Dowsett M: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9: 524S-532S, 2003.
35. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE and Nicholson RI: The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144: 5105-5117, 2003.
36. Leitzel K, Souder C, Ali S, Demers L, Evans DB, Chaudri-Ross H, Hamer P, Carney W and Lipton A: Serum EGFR/HER-2 combination predicts poor survival in metastatic breast cancer. Proceedings of ASCO, Abstract No. 9613, 2005.
37. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM and Ingle JN: A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 13: 1225-1235, 2002.